4-aminopyridine


Also found in: Encyclopedia, Wikipedia.

4-aminopyridine

1. a central nervous system stimulant and a pharmacological antagonist to d-tubocurarine and ketamine-diazepam. Used experimentally as a neuromuscular potentiator in the treatment of botulism.
2. a bird repellent which will poison animals that eat the treated grain accidentally. Horses show fright, sweating, convulsions and sudden death.
References in periodicals archive ?
Fatigue in progressive multiple sclerosis: results of a randomized, doubleblind, placebo-controlled, crossover trial of oral 4-aminopyridine.
Jay Meythaler, head of NRI's Scientific Advisory Board, commented, "We are encouraged by the orphan drug designation of 4-Aminopyridine for the treatment of chronic functional motor and sensory deficits from Guillain-Barre Syndrome.
This randomized, double-blind, placebo-controlled study examined the efficacy and safety of 4-aminopyridine (4-AP).
Also used as catalysts were 4-pyrrolidinopyridine and polyDMAP (polymer-bound 4-aminopyridine from Reilly Industries, Inc.
6b Substance P, bethanechol, 4-aminopyridine, and potassium
To exploit this temperature dependence, Floyd Davis and colleagues at Rush Medical College in Chicago have been working with 4-aminopyridine, a chemical that mimics the effect of cold on nerves.
AMPYRA is contraindicated in patients with a history of hypersensitivity to Ampyra or 4-aminopyridine.
9-( tetrahydro-2-furanyl)-9H-purine-6-amine (SQ22536), charybdotoxin (CTX), apamin, 4-aminopyridine (4-AP), glibenclamide and Ba[Cl.
It has also been shown that in the juvenile rat hippocampus, 4-aminopyridine, a GABAergic agent, induces a glutamatergic independent synchronous potential that is due to GABA released from inhibitory terminals, and is associated with an increase in extracellular potassium which influences neuronal excitability and thus determines some of the features of the epileptiform discharge including duration and ability to propagate to distant areas (15).
Efficacy and safety of 4-aminopyridine in patients with longterm spinal cord injury: A randomized, double-blind, placebo-controlled trial.
Studies have also been conducted with the potassium channel blockers 4-aminopyridine and 3,4-diaminopyridine (neither is currently marketed in the United States).